PTGX 64.83 ▼ -0.23% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Protagonist Therapeutics ...

    NASDAQ: PTGX · Real-Time Price · USD
    64.83
    -0.15 (-0.23%)
    At close: Oct 03, 2025, 3:59 PM
    64.83
    0.00%
    After-hours: Oct 03, 2025, 04:10 PM EDT
    -0.23%
    Bid 62.2
    Market Cap 4.03B
    Revenue (ttm) 203.63M
    Net Income (ttm) 52.04M
    EPS (ttm) 0.69
    PE Ratio (ttm) 93.96
    Forward PE -6498
    Analyst Buy
    Dividends n/a
    Ask 66
    Volume 612,543
    Avg. Volume (20D) 842,592
    Open 64.59
    Previous Close 64.98
    Day's Range 64.56 - 65.36
    52-Week Range 33.31 - 68.26
    Beta 2.20
    Ex-Dividend Date n/a

    About PTGX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PTGX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Protagonist Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    6 months ago
    +45.89%
    Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription
    7 months ago
    +2.42%
    Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.
    news image

    3 weeks ago · seekingalpha.com

    Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

    Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Di...

    news image

    1 month ago · seekingalpha.com

    Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

    Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conferen...

    news image

    1 month ago · accessnewswire.com

    Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

    NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

    news image

    1 month ago · fool.com

    Protagonist (PTGX) Q2 Revenue Falls 26%

    Protagonist (PTGX) Q2 Revenue Falls 26%

    news image

    1 month ago · zacks.com

    Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

    Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.

    news image

    1 month ago · accessnewswire.com

    Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of ico...

    Add to Watchlist